Azenosertib not checked
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · ZN-c3
FollowEvery change as it happens, and a Monday email
Trials
3 active
12 in total · 7 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Main trialPhase 3
- “This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.”In the company’s words, NCT07546500 on ClinicalTrials.gov
- Other names
- ZN-c3
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
- AxitinibPfizer · Phase 3
Coming up3
- 1 DecPhase 2 trial completes · ClinicalTrials.gov
- 31 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 May 2028 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression | |
| Phase 2Recruiting | 1 Dec 2026 | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | |
| Phase 1Recruiting | 30 Jun 2028 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer | |
| Phase 2Completed | 22 Oct 2025 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | |
| Phase 1/2Terminated | 2 Jul 2024 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | |
| Phase 1/2Completed | 15 Oct 2025 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | |
| Phase 1Unknown | 30 Jun 2022 | A Phase 1b Study of ZN-c3 in Chinese Subjects | |
| Phase 1Completed | 30 Aug 2023 | A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma | |
| Phase 1Terminated | 16 Jul 2024 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | |
| Phase 1Completed | 6 May 2025 | A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors | |
| Phase 1/2Ended | not given | Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER | |
| Phase 1Suspended | not given | PHASE Ib STUDY WITH THE COMBINATION OF LB−100 (PP2A INHIBITOR) AND AZENOSERTIB (WEE1 INHIBITOR) IN PATIENTS WITH METASTATIC COLORECTAL CANCER The COLLEE trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026